Less nausea, more insulin sensitivity, and a little less inflammation Part 2 in a series on GIP
The master incretin of the alpha and beta cell starts to shinePart 1 in a series on GIP
Lilly's oral non-peptide GLP-1 could change everything & bimagrumab flexes its muscle, but at what cost?
Novo's Dual Amylin-GLP1 agonist shows promise but caveats apply
